This article was originally published in The Tan Sheet
Executive SummaryHigh blood levels of homocysteine can lead to impaired mental ability in the elderly; however, vitamin B may offset decline, a new study published in the Oct. 1 American Journal of Epidemiology suggests. "Plasma total homocysteine (tHcy) concentrations are associated with deficits in cognitive performance in persons free from dementia," Merrill Elias, MD, Boston University, et al., find. However, "treatment with folate, vitamin B6 and vitamin B12 may result in lowering of homocysteine." The study was conducted as part of the Framingham Offspring Study, an ongoing survey tracking community health in Framingham, Mass. Using data collected between 1991 and 2002, researchers examined 2,096 patients over the age of 40 who were free of stroke and dementia. The subjects were divided according to age. "Statistically significant inverse associations between tHcy and multiple cognitive domains were observed for individuals aged 60 or more years; no such associations were observed for participants aged less than 60 years," the study states...
You may also be interested in...
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.